Celsius Therapeutics snags $65 mln Series A
Cambridge, Massachusetts-based Celsius Therapeutics, which translates single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer, has raised $65 million in Series A financing. Third Rock Ventures led the round with participation from other investors that included GV, Heritage Provider Network, Casdin Capital and Alexandria Venture Investments.
15 May 2018•1 min read
